Skip to content

What changes for human health?

Health.

Understand the evidence behind emerging treatments, tools and health claims.

Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D

FDA approval gives chronic hepatitis D a US treatment pathway. The harder question is whether evidence, diagnosis, price and payer access can catch up.

Biotech 6 Jun 2026 7 min read

Global Cancer Workforce Crisis: Why Better Treatments Still Need a Capacity Stack

A Lancet Oncology Commission turns cancer care into an infrastructure story: survival depends on people, diagnostics, equipment, and capacity.

Health 3 Jun 2026 6 min read

Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.

Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.

Longevity 2 Jun 2026 6 min read

Rapamycin Still Needs Human Proof

Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.

Longevity 13 May 2026 6 min read

Partial Epigenetic Reprogramming Human Trial: Longevity’s Reality Check

ER-100 is a narrow eye-disease trial, but it may be the first real test of whether cellular rejuvenation can survive clinical evidence.

Longevity 12 May 2026 5 min read

The First Human Rejuvenation Trial: What ER-100 Really Changes

ER-100 matters because rejuvenation language is finally being forced to answer to medicine.

Longevity 9 Jan 2026 5 min read

Prime Editing in Humans: First Proof, Big Questions Ahead

Prime editing has crossed from elegant theory into the clinic, but the hardest questions are still ahead.

Biotech 24 Aug 2025 4 min read

Personalized Gene Editing for One Baby Is a Breakthrough—And a Stress Test for Medicine

A baby’s personalized CRISPR treatment shows what precision medicine can become. It also exposes the manufacturing, regulatory, and access problems medicine has not solved yet.

Biotech 6 Jul 2025 5 min read

The Vastkind Briefing

Stay ahead
of the story.

A personal take on the week. By Dorian.

Occasional editions. Free to subscribe.
Unsubscribe anytime.